Lantern Pharma (NASDAQ: LTRN) has announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern's RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
Lantern Pharma is a clinical-stage precision oncology company leveraging artificial intelligence, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Additionally, withZeta.ai, Lantern's multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
This expansion of the predictBBB platform into an LQM represents a significant advancement in computational drug discovery. By providing researchers with rapid, high-dimensional analysis from a single SMILES input, the platform aims to accelerate the identification of promising drug candidates and reduce the time and cost associated with early-stage drug development. The integration with Lantern's RADR AI technology ensures that the analysis is benchmarked and validated, offering reliable insights for researchers.
For more information, visit the full press release at https://ibn.fm/XqWld. To stay updated on the latest news and updates relating to LTRN, visit the company's newsroom at https://ibn.fm/LTRN.
